Literature DB >> 22513409

Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin.

Hiroshi Watanabe1, Tsuyoshi Noguchi, Yohei Miyamoto, Daisuke Kadowaki, Shunsuke Kotani, Makoto Nakajima, Shigeyuki Miyamura, Yu Ishima, Masaki Otagiri, Toru Maruyama.   

Abstract

Recently, p-cresyl sulfate (PCS) has been identified as a protein-bound uremic toxin. Moreover, the serum-free concentration of PCS, which is associated with its efficacy of hemodialysis, appears to be a good predictor of survival in chronic kidney disease (CKD). We previously found that PCS interacts with indoxyl sulfate (IS), another sulfate-conjugated uremic toxin, during renal excretion via a common transporter. The purpose of this study was to further investigate the interaction between PCS and IS on the binding to human serum albumin (HSA). Here, we used ultrafiltration to show that there is only one high-affinity binding site for PCS, with a binding constant on the order of 10(5) M(-1) (i.e., comparable to that of IS). However, a binding constant of the low-affinity binding site for PCS is 2.5-fold greater than that for IS. Displacement of a fluorescence probe showed that PCS mainly binds to site II, which is the high-affinity site for PCS, on HSA. This finding was further supported by experiments using mutant HSA (R410A/Y411A) that displayed reduced site II ligand binding. A Klotz analysis showed that there could be competitive inhibition between PCS and IS on HSA binding. A similar interaction between PCS and IS on HSA was also observed under the conditions mimicking CKD stage 4 to 5. The present study suggests that competitive interactions between PCS and IS in both HSA binding and the renal excretion process could contribute to fluctuations in their free serum concentrations in patients with CKD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513409     DOI: 10.1124/dmd.112.045617

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

1.  Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD.

Authors:  Ruben Poesen; Pieter Evenepoel; Henriette de Loor; Dirk Kuypers; Patrick Augustijns; Björn Meijers
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-15       Impact factor: 8.237

2.  Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor.

Authors:  Magdalena Madero; Karla B Cano; Israel Campos; Xia Tao; Vaibhav Maheshwari; Jillian Brown; Beatriz Cornejo; Garry Handelman; Stephan Thijssen; Peter Kotanko
Journal:  Clin J Am Soc Nephrol       Date:  2019-02-12       Impact factor: 8.237

3.  Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure.

Authors:  Ken-ichi Fujita; Yusuke Masuo; Hidenori Okumura; Yusuke Watanabe; Hiromichi Suzuki; Yu Sunakawa; Ken Shimada; Kaori Kawara; Yuko Akiyama; Masanori Kitamura; Munetaka Kunishima; Yasutsuna Sasaki; Yukio Kato
Journal:  Pharm Res       Date:  2015-09-03       Impact factor: 4.200

4.  Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin.

Authors:  Hiroshi Watanabe; Yoshiaki Sakaguchi; Ryusei Sugimoto; Ken-Ichi Kaneko; Hiroshi Iwata; Shunsuke Kotani; Makoto Nakajima; Yu Ishima; Masaki Otagiri; Toru Maruyama
Journal:  Clin Exp Nephrol       Date:  2013-11-02       Impact factor: 2.801

5.  p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress.

Authors:  Hiroshi Watanabe; Yohei Miyamoto; Yuki Enoki; Yu Ishima; Daisuke Kadowaki; Shunsuke Kotani; Makoto Nakajima; Motoko Tanaka; Kazutaka Matsushita; Yoshitaka Mori; Takatoshi Kakuta; Masafumi Fukagawa; Masaki Otagiri; Toru Maruyama
Journal:  Pharmacol Res Perspect       Date:  2014-11-07

6.  Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.

Authors:  Yuki Enoki; Hiroshi Watanabe; Riho Arake; Rui Fujimura; Kana Ishiodori; Tadashi Imafuku; Kento Nishida; Ryusei Sugimoto; Saori Nagao; Shigeyuki Miyamura; Yu Ishima; Motoko Tanaka; Kazutaka Matsushita; Hirotaka Komaba; Masafumi Fukagawa; Masaki Otagiri; Toru Maruyama
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-06-12       Impact factor: 12.910

7.  Binding affinity and capacity for the uremic toxin indoxyl sulfate.

Authors:  Eric Devine; Detlef H Krieter; Marieke Rüth; Joachim Jankovski; Horst-Dieter Lemke
Journal:  Toxins (Basel)       Date:  2014-01-24       Impact factor: 4.546

8.  Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an in vitro human whole blood study.

Authors:  Xia Tao; Stephan Thijssen; Peter Kotanko; Chih-Hu Ho; Michael Henrie; Eric Stroup; Garry Handelman
Journal:  Sci Rep       Date:  2016-03-22       Impact factor: 4.379

9.  Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1.

Authors:  Yuki Enoki; Hiroshi Watanabe; Riho Arake; Ryusei Sugimoto; Tadashi Imafuku; Yuna Tominaga; Yu Ishima; Shunsuke Kotani; Makoto Nakajima; Motoko Tanaka; Kazutaka Matsushita; Masafumi Fukagawa; Masaki Otagiri; Toru Maruyama
Journal:  Sci Rep       Date:  2016-08-23       Impact factor: 4.379

10.  The effect of isohydric hemodialysis on the binding and removal of uremic retention solutes.

Authors:  Aleksey Etinger; Sumit R Kumar; William Ackley; Leland Soiefer; Jonathan Chun; Prabjhot Singh; Eric Grossman; Albert Matalon; Robert S Holzman; Bjorn Meijers; Jerome Lowenstein
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.